Published in PLoS One on January 19, 2012
E-type prostanoid receptor 4 (EP4) in disease and therapy. Pharmacol Ther (2013) 1.28
A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells. Apoptosis (2014) 0.95
Antitumor activity of the selective cyclooxygenase-2 inhibitor, celecoxib, on breast cancer in Vitro and in Vivo. Cancer Cell Int (2012) 0.91
ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma. Front Oncol (2012) 0.90
Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer. Prostaglandins Other Lipid Mediat (2014) 0.86
COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset. Proc Natl Acad Sci U S A (2015) 0.83
The roles of beta-adrenergic receptors in tumorigenesis and the possible use of beta-adrenergic blockers for cancer treatment: possible genetic and cell-signaling mechanisms. Cancer Manag Res (2012) 0.81
Dying endothelial cells stimulate proliferation of malignant glioma cells via a caspase 3-mediated pathway. Oncol Lett (2013) 0.80
Dysregulated CRTC1 activity is a novel component of PGE2 signaling that contributes to colon cancer growth. Oncogene (2015) 0.77
Prostaglandin E2 promotes MYCN non-amplified neuroblastoma cell survival via β-catenin stabilization. J Cell Mol Med (2014) 0.77
Odontogenic epithelial proliferation is correlated with COX-2 expression in dentigerous cyst and ameloblastoma. Exp Ther Med (2016) 0.75
Decursinol angelate inhibits PGE2-induced survival of the human leukemia HL-60 cell line via regulation of the EP2 receptor and NFκB pathway. Cancer Biol Ther (2016) 0.75
The SK-N-AS human neuroblastoma cell line develops osteolytic bone metastases with increased angiogenesis and COX-2 expression. J Bone Oncol (2014) 0.75
COX2 expression in neuroblastoma increases tumorigenicity but does not affect cell death in response to the COX2 inhibitor celecoxib. Clin Exp Metastasis (2014) 0.75
Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med (2005) 15.46
Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer (2003) 10.88
G-protein-coupled receptors and cancer. Nat Rev Cancer (2007) 6.80
Eicosanoids and cancer. Nat Rev Cancer (2010) 5.96
A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP. Cell (1991) 5.84
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis. Science (2005) 5.68
Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice. Nat Med (2001) 2.98
Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer (2007) 2.65
Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell (2004) 2.60
Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. J Clin Oncol (2010) 2.32
Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis. Cancer Res (2002) 2.02
High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A (2010) 1.92
Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res (2007) 1.76
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 1.70
Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res (1999) 1.65
Simultaneous quantification of arachidonic acid metabolites in cultured tumor cells using high-performance liquid chromatography/electrospray ionization tandem mass spectrometry. Anal Biochem (2001) 1.38
Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene (2007) 1.36
Intracrine signaling through lipid mediators and their cognate nuclear G-protein-coupled receptors: a paradigm based on PGE2, PAF, and LPA1 receptors. Can J Physiol Pharmacol (2006) 1.35
Mediators of PGE2 synthesis and signalling downstream of COX-2 represent potential targets for the prevention/treatment of colorectal cancer. Biochim Biophys Acta (2006) 1.33
Prostanoid receptor antagonists: development strategies and therapeutic applications. Br J Pharmacol (2009) 1.31
Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci U S A (1998) 1.29
Localization of functional prostaglandin E2 receptors EP3 and EP4 in the nuclear envelope. J Biol Chem (1999) 1.27
EPAC proteins transduce diverse cellular actions of cAMP. Br J Pharmacol (2009) 1.25
Coxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention. Cancer Prev Res (Phila) (2011) 1.20
Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry (1994) 1.20
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res (2004) 1.15
Protein kinase A as a biological target in cancer therapy. Expert Opin Ther Targets (2009) 1.09
Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics (2011) 1.06
Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res (2007) 1.02
Perifosine-induced inhibition of Akt attenuates brain-derived neurotrophic factor/TrkB-induced chemoresistance in neuroblastoma in vivo. Cancer (2011) 1.02
Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol (2005) 1.01
Epigenetic silencing of prostaglandin E receptor 2 (PTGER2) is associated with progression of neuroblastomas. Oncogene (2007) 1.00
Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer (2011) 0.99
Ovarian epithelial cancer: a role for PGE2-synthesis and signalling in malignant transformation and progression. Mol Cancer (2006) 0.99
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol (2008) 0.97
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer (2011) 0.97
Defects in cAMP-pathway may initiate carcinogenesis in dividing nerve cells: a review. Apoptosis (2003) 0.95
Prostanoid receptor expression in colorectal cancer related to tumor stage, differentiation and progression. Acta Oncol (2007) 0.94
Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene (2006) 0.92
Prostaglandin E receptor EP1 suppresses breast cancer metastasis and is linked to survival differences and cancer disparities. Mol Cancer Res (2010) 0.92
Expressions of cyclooxygenase-2 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res (2002) 0.92
Combined effects of prostaglandin E receptor subtype EP1 and subtype EP4 antagonists on intestinal tumorigenesis in adenomatous polyposis coli gene knockout mice. Cancer Sci (2003) 0.91
Differential expression of E-prostanoid receptors in human hepatocellular carcinoma. Int J Cancer (2008) 0.86
Relationship between prostaglandin E2 receptors and clinicopathologic features in human prostate cancer tissue. Urology (2006) 0.86
AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther (2008) 0.84
Dickkopf-3 expression is a marker for neuroblastic tumor maturation and is down-regulated by MYCN. Int J Cancer (2008) 0.84
Phospholipid fatty acids and neurotoxicity in human neuroblastoma SH-SY5Y cells. Neurosci Lett (2001) 0.84
Prolonged low-dose administration of the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts. Cancer Sci (2009) 0.82
Potentiation of PGE(2)-mediated cAMP production during neuronal differentiation of human neuroblastoma SK-N-BE(2)C cells. J Neurochem (2001) 0.82
PGE(2) receptors and synthesis in human gastric mucosa: perturbation in cancer. Prostaglandins Leukot Essent Fatty Acids (2002) 0.80
Mitochondria, oxidative stress and cell death. Apoptosis (2007) 4.29
Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol (2007) 3.90
Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci U S A (2002) 3.57
MYC in oncogenesis and as a target for cancer therapies. Adv Cancer Res (2010) 2.00
High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci U S A (2010) 1.92
Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J Clin Invest (2011) 1.87
High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J (2008) 1.83
Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification. Clin Cancer Res (2010) 1.79
RNA helicase A is a downstream mediator of KIF1Bβ tumor-suppressor function in neuroblastoma. Cancer Discov (2014) 1.58
Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma. BMC Cancer (2011) 1.45
Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells. Exp Hematol (2008) 1.34
L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology (2009) 1.33
MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A (2013) 1.33
Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res (2009) 1.24
Randomized Trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the European HR-NBL1/SIOPEN study. J Clin Oncol (2010) 1.24
High-resolution array copy number analyses for detection of deletion, gain, amplification and copy-neutral LOH in primary neuroblastoma tumors: four cases of homozygous deletions of the CDKN2A gene. BMC Genomics (2008) 1.22
Processed caspase-2 can induce mitochondria-mediated apoptosis independently of its enzymatic activity. EMBO Rep (2004) 1.21
Caspase-2 permeabilizes the outer mitochondrial membrane and disrupts the binding of cytochrome c to anionic phospholipids. J Biol Chem (2004) 1.20
Screening for gene mutations in a 500 kb neuroblastoma tumor suppressor candidate region in chromosome 1p; mutation and stage-specific expression in UBE4B/UFD2. Oncogene (2003) 1.20
The antimicrobial peptide, lactoferricin B, is cytotoxic to neuroblastoma cells in vitro and inhibits xenograft growth in vivo. Int J Cancer (2006) 1.18
Frequent detection of human cytomegalovirus in neuroblastoma: a novel therapeutic target? Int J Cancer (2013) 1.16
Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res (2004) 1.15
Cell culture and Drosophila model systems define three classes of anaplastic lymphoma kinase mutations in neuroblastoma. Dis Model Mech (2012) 1.14
Targeting the hedgehog signal transduction pathway at the level of GLI inhibits neuroblastoma cell growth in vitro and in vivo. Int J Cancer (2012) 1.13
Cardiolipin is not required for Bax-mediated cytochrome c release from yeast mitochondria. J Biol Chem (2003) 1.11
Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J (2009) 1.08
Human articular chondrocytes express ChemR23 and chemerin; ChemR23 promotes inflammatory signalling upon binding the ligand chemerin(21-157). Arthritis Res Ther (2010) 1.07
Appearance of the novel activating F1174S ALK mutation in neuroblastoma correlates with aggressive tumor progression and unresponsiveness to therapy. Cancer Res (2010) 1.07
Comprehensive SNP array study of frequently used neuroblastoma cell lines; copy neutral loss of heterozygosity is common in the cell lines but uncommon in primary tumors. BMC Genomics (2011) 1.06
Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma. Carcinogenesis (2013) 1.05
Multiple roles of microsomal glutathione transferase 1 in cellular protection: a mechanistic study. Free Radic Biol Med (2010) 1.04
Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin Cancer Res (2007) 1.02
Expression of enzymes and receptors of the leukotriene pathway in human neuroblastoma promotes tumor survival and provides a target for therapy. FASEB J (2008) 1.01
The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma. Mol Cancer (2012) 1.01
MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma. Carcinogenesis (2011) 1.00
Serious illness in childhood: the different threats of cancer and diabetes from a parent perspective. J Pediatr (2004) 0.99
Effects of small molecule inhibitors of PI3K/Akt/mTOR signaling on neuroblastoma growth in vitro and in vivo. Int J Cancer (2011) 0.99
Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res (2013) 0.99
Autophagy and metacaspase determine the mode of cell death in plants. J Cell Biol (2013) 0.99
Microsomal glutathione transferase 1 protects against toxicity induced by silica nanoparticles but not by zinc oxide nanoparticles. ACS Nano (2012) 0.98
Gangliocytes in neuroblastic tumors express alarin, a novel peptide derived by differential splicing of the galanin-like peptide gene. J Mol Neurosci (2006) 0.98
The Ras effectors NORE1A and RASSF1A are frequently inactivated in pheochromocytoma and abdominal paraganglioma. Endocr Relat Cancer (2007) 0.98
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol (2008) 0.97
Embryonal neural tumours and cell death. Apoptosis (2009) 0.97
Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Exp Cell Res (2006) 0.97
Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells. Proc Natl Acad Sci U S A (2009) 0.96
Omega-3 fatty acids in cancer, the protectors of good and the killers of evil? Exp Cell Res (2010) 0.96
Reactive oxygen species generated in different compartments induce cell death, survival, or senescence. Free Radic Biol Med (2013) 0.96
Oxidative modification sensitizes mitochondrial apoptosis-inducing factor to calpain-mediated processing. Free Radic Biol Med (2010) 0.94
The influence of pediatric cancer diagnosis and illness complication factors on parental distress. J Pediatr Hematol Oncol (2008) 0.93
Quantitative analysis of tyrosine hydroxylase mRNA for sensitive detection of neuroblastoma cells in blood and bone marrow. Clin Chem (2003) 0.92
Stage-dependent expression of PI3K/Akt‑pathway genes in neuroblastoma. Int J Oncol (2012) 0.91
Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo. Int J Cancer (2010) 0.90
Protective role of humanin on bortezomib-induced bone growth impairment in anticancer treatment. J Natl Cancer Inst (2014) 0.90
Birth characteristics and Wilms tumors in children in the Nordic countries: a register-based case-control study. Int J Cancer (2011) 0.90
Tumor development, growth characteristics and spectrum of genetic aberrations in the TH-MYCN mouse model of neuroblastoma. PLoS One (2012) 0.90
Synergistic induction of apoptosis in neuroblastoma cells using a combination of cytostatic drugs with interferon-gamma and TRAIL. Int J Oncol (2004) 0.89
Targeting hepatoma using nitric oxide donor strategies. Antioxid Redox Signal (2012) 0.89
Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF. Br J Haematol (2010) 0.89
Metronomic scheduling of imatinib abrogates clonogenicity of neuroblastoma cells and enhances their susceptibility to selected chemotherapeutic drugs in vitro and in vivo. Int J Cancer (2009) 0.88
Verification of genes differentially expressed in neuroblastoma tumours: a study of potential tumour suppressor genes. BMC Med Genomics (2009) 0.88
Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer (2006) 0.88
Colon carcinoma cell interaction with liver sinusoidal endothelium inhibits organ-specific antitumor immunity through interleukin-1-induced mannose receptor in mice. Hepatology (2010) 0.88
Release of mitochondrial DNA fragments from brain mitochondria of irradiated mice. Mitochondrion (2006) 0.87
Estimated GFR is biased by non-traditional cardiovascular risk factors. Am J Nephrol (2015) 0.87
Apoptosis and tumor remission in liver tumor xenografts by 4-phenylbutyrate. Int J Oncol (2003) 0.87
The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes. Oncoimmunology (2013) 0.87
mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer (2008) 0.86
Arsenic stimulates release of cytochrome c from isolated mitochondria via induction of mitochondrial permeability transition. Toxicol Appl Pharmacol (2005) 0.86
Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis. Int J Oncol (2013) 0.86
The Phox2 pathway is differentially expressed in neuroblastoma tumors, but no mutations were found in the candidate tumor suppressor gene PHOX2A. Int J Oncol (2009) 0.86
Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes. Cancer Res (2003) 0.86
Resveratrol induces SIRT1- and energy-stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment. Cancer Chemother Pharmacol (2011) 0.86
Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biol Ther (2005) 0.86
NSAIDs in neuroblastoma therapy. Cancer Lett (2005) 0.86